Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Filgotinib in Idiopathic Multicentric Castleman Disease
jRCT2071230108Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of filgotinib in idiopathic multicentric Castleman disease (iMCD), sponsored by Gilead Sciences. Primary endpoints: Safety and tolerability of filgotinib and Safety laboratory and imaging assessments. Started Jan 2024; status: completed.
02
Drugs
filgotinib
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on jRCT2071230108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230108.